Aldeyra Therapeutics (Aldeyra Therapeutics) Interest Expense : $-2.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Aldeyra Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aldeyra Therapeutics's interest expense for the three months ended in Mar. 2024 was $ -0.50 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.08 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aldeyra Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -9.39 Mil. Aldeyra Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ -0.50 Mil. Aldeyra Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aldeyra Therapeutics Interest Expense Historical Data

The historical data trend for Aldeyra Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Interest Expense Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.60

-1.90

-1.74

-1.69

-2.07

Aldeyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.49	-0.53	-0.54	-0.51	-0.50

Aldeyra Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.08 Mil.

Aldeyra Therapeutics (NAS:ALDX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aldeyra Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $-0.50 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-9.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.21 Mil.

Aldeyra Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Aldeyra Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (NAS:ALDX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

137:Germany 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd C Brady	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Martin Joseph Joyce	director	1050 HINGHAM STREET, ROCKLAND MA 02370
Bruce Greenberg	officer: See Remarks	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Stephen Machatha	officer: Chief Development Officer	131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Ben Bronstein	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
David Mcmullin	officer: SVP Corp. Dev. & Strategy	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Jesse I Treu	director, 10 percent owner
Stephen J Tulipano	officer: Chief Financial Officer	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140